MedTrace Logo

Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease

NCT04603729 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-10-27

No results posted yet for this study

Summary

The investigator will select participants with moderate to severe covid 19 disease admitted in Fatima memorial hospital. The investigator will divide them in two groups according to convenience sampling. Group 1 will be given dexamethasone 8mg/day and group 2 will be given methylprednisolone 1mg/kg/day IV for 5 days. The investigator will compare the improvement in temperature, oxygen requirement and CRP level at day zero and day 5 in both the groups.

Conditions

  • Covid 19 Disease

Interventions

DRUG

Dexamethasone 2 MG/ML

Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants

DRUG

Methylprednisolone Injection

methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants

Sponsors & Collaborators

  • Fatima Memorial Hospital

    lead OTHER

Principal Investigators

  • Khurshid A Khan, MBBS, FACM · Fatima Memorial Hospital

  • Arzinda F Syeda, MBBS, FCPS · Fatima Memorial Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-30
Primary Completion
2020-06-30
Completion
2020-07-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04603729 on ClinicalTrials.gov